NLGN2 was identified as a favorable prognostic factor in the tumor lymph node non-metastatic (-) patients (HR, 0.65; 95%CI, 0.44 to 0.97; p < 0.05) (Figure 3A), but not in the tumor lymph node metastatic (+) patients (HR, 0.92; 95%CI, 0.72 to 1.19; p > 0.05) (Figure 3B). Here, NLGN2 is linked to neoplasm.